Generic drugs of tucatinib/tucatinib: Overseas production and market overview

Tucatinib/The original drug Tucatinib has been successfully launched in many overseas countries and is widely used in oral treatment fields such as breast cancer and colorectal cancer. Recently, generic drugs of tucatinib have also emerged in overseas markets. These generic drugs are highly similar to the original drug in core ingredients, but may have certain differences in product specifications, pricing strategies, etc. At present, well-known generic drug manufacturers include the Second Pharmaceutical Factory of Laos, Ziska Pharmaceuticals of Bangladesh, and Everest Pharmaceuticals of Bangladesh.

Tucatinib, as an oral drug, is a potent inhibitor of the tyrosine kinase of the HER2 protein. HER2 protein is overexpressed in various cancers, including breast cancer, colorectal cancer, and gastric cancer. In preclinical in vitro experiments, tucatinib has shown an inhibitory effect on the phosphorylation of HER2 and HER3, thereby blocking the downstream MAPK and AKT signaling pathways and inhibiting the growth of cancer cells. At the same time, it also exhibits significant anti-tumor effects in tumor cells expressing HER2. When tucatinib was combined with the anti-HER2 antibody trastuzumab, its antitumor activity in vitro and in vivo was significantly enhanced.

Neither the original drug of tucatinib nor its generic drugs have entered the domestic market yet. In Europe, The original drug tucatinib in 150 mg and 60 tablets may be sold for more than 70,000 yuan per box (the price will fluctuate with exchange rate changes). In contrast, the price of 150 mg 30 tablets of generic drugs produced by Bangladeshi pharmaceutical factories is much more affordable, about more than 4,000 yuan (the price may also change due to the exchange rate).